logo
Sign in

Elektrofi Inc

Boston, MA · Biotech · Acquired

Electroporation-based drug delivery system for biologics administration

Claim this profile

Follows are private to you and power your alerts

Updated · elektrofi.com

Sector
Biotech
Headquarters
Boston, MA
Latest Form D
$96.5M, Aug 2024
Total capital
$141M
Federal grants
$2.5M
3 awards · 2017–2021
Rank in peer group#17 of 20
Private capital raised
$139M
2 Form D · last Aug 2024
26 months since last filing
Federal contracts
None on recordNo federal contract awards found.
Granted patents
11
29 pending · first 2021
Rank in peer group#3 of 20

Capital timeline

20172018201920202021202220232024FEDERAL ↑EQUITY ↓Cumulative $141M$225K$750K$1.5M1st Form D$42.5M2nd Form D$96.5M
2017201920212023FEDERAL ↑EQUITY ↓Cumulative $141M$225K$750K$1.5M1st Form D$42.5M

Latest events

  • Private capital raisedForm D · SEC · 2nd filing$96.5M
  • Private capital raisedForm D · SEC · 1st filing$42.5M
  • Federal grantDefense · Phase II · Ultra-high Concentration Protein Delivery Formulation Technology for the Rapid Deployment of Treatments of COVID-19 and Future Pandemics$1.5M
  • Federal grantNSF · Phase II · SBIR Phase II: Novel Formulation for the Delivery of High Concentration Protein Therapeutics$750K
  • Federal grantNSF · Phase I · SBIR Phase I: Novel Formulation for the Delivery of High Concentration Protein Therapeutics$225K

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Federal first

60months

from Elektrofi Inc’s first federal award to its first private round.

First federal award · Jul 2017
NSF · $225K
First Form D · Jun 2022
$42.5M · 1st Form D
Awards before first raise
3 awards

An association in public records, not a cause or a prediction.

Standing among 20 peers

Line = median

Biotech · Material

  • Federal grantsBelow median
  • Granted patents#3 · top 15%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

Researcher links verified by same-company patents and grants
  • Chase CoffmanResearcherDirector, Executive OfficerLinked by 2 patents
  • Andrew L. GoldbergDirectorNamed in SEC Form D filings
  • Arman L. GuptaDirectorNamed in SEC Form D filings
  • Charles L. CooneyDirectorNamed in SEC Form D filings
  • Constantine L. ChinoporosDirectorNamed in SEC Form D filings
  • Jason NorrisDirector, Executive OfficerNamed in SEC Form D filings
Show all 8 people
  • Noel L. JeeDirectorNamed in SEC Form D filings
  • Peter L. BojoDirectorNamed in SEC Form D filings

What it has protected

USPTO · 11 granted of 40
  • PendingPeptide Particles And Methods Of FormationUSPTOApplication 19318998
  • GrantedParticle Formation And MorphologyUSPTOUS 12,558,323
  • PendingParticles Comprising A Therapeutic Or Diagnostic Agent And Suspensions And Methods Of Use ThereofUSPTOApplication 19321930
Show all 40 patent records

Related companies, and why

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through . SBIR and STTR awards through .